Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Sponsor

Roswell Park Cancer Institute (Other)

Overall Status

Completed

CT.gov ID

NCT01522820

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arms

Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Anaplastic Astrocytoma Anaplastic Oligoastrocytoma Anaplastic Oligodendroglioma Estrogen Receptor Negative Estrogen Receptor Positive Glioblastoma Hormone-Resistant Prostate Cancer Metastatic Prostate Carcinoma Metastatic Renal Cell Cancer Recurrent Adult Brain Neoplasm Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Hepatocellular Carcinoma Recurrent Lung Carcinoma Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Prostate Carcinoma Recurrent Renal Cell Carcinoma Recurrent Uterine Corpus Carcinoma Resectable Hepatocellular Carcinoma Sarcoma Stage IA Breast Cancer Stage IA Ovarian Cancer Stage IA Uterine Corpus Cancer Stage IB Breast Cancer Stage IB Ovarian Cancer Stage IB Uterine Corpus Cancer Stage IC Ovarian Cancer Stage II Uterine Corpus Cancer Stage IIA Breast Cancer Stage IIA Lung Carcinoma Stage IIA Ovarian Cancer Stage IIB Breast Cancer Stage IIB Esophageal Cancer Stage IIB Lung Carcinoma Stage IIB Ovarian Cancer Stage IIB Skin Melanoma Stage IIC Ovarian Cancer Stage IIC Skin Melanoma Stage IIIA Breast Cancer Stage IIIA Esophageal Cancer Stage IIIA Lung Carcinoma Stage IIIA Ovarian Cancer Stage IIIA Skin Melanoma Stage IIIA Uterine Corpus Cancer Stage IIIB Breast Cancer Stage IIIB Esophageal Cancer Stage IIIB Ovarian Cancer Stage IIIB Skin Melanoma Stage IIIB Uterine Corpus Cancer Stage IIIC Breast Cancer Stage IIIC Esophageal Cancer Stage IIIC Ovarian Cancer Stage IIIC Skin Melanoma Stage IIIC Uterine Corpus Cancer Stage IV Bladder Urothelial Carcinoma Stage IV Esophageal Cancer Stage IV Ovarian Cancer Stage IV Prostate Cancer Stage IV Skin Melanoma Stage IVA Uterine Corpus Cancer Stage IVB Uterine Corpus Cancer	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: Sirolimus	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

Determine the safety of DC205-NY-ESO-1 vaccine (DEC-205/NY-ESO-1 fusion protein CDX-1401) with and without sirolimus. Toxicity as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

SECONDARY OBJECTIVES:

I. Assess the NY-ESO-1 specific cellular and humoral immunity:

Peripheral blood NY-ESO-1 specific cluster of differentiation (CD)8+ and CD4+ T-cells.
Peripheral blood NY-ESO-1 specific antibodies.
Peripheral blood frequency of CD4+CD25+forkhead box P3 (FOXP3)+ regulatory T-cells.

TERTIARY OBJECTIVES:

Explore time to disease progression.

OUTLINE:

Patients undergo standard collection of peripheral white blood cells via leukapheresis over 90-240 minutes for vaccine preparation. Patients are assigned sequentially to Cohorts 1a-1d.

COHORT 1a: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intranodally on days 1, 29, 57, and 113.

COHORT 1b: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus orally (PO) on days 1-14, 29-42, and 57-70.

COHORT 1c: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or percutaneous endoscopic gastrostomy (PEG) tube on days 15-28, 43-56, and 71-84.

COHORT 1d: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.

COHORT 2: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.

After completion of study treatment, patients are followed up at 6 weeks, 6 months and 12 months.

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors

Study Start Date :

Mar 1, 2012

Actual Primary Completion Date :

Jul 1, 2016

Actual Study Completion Date :

Jul 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1a (vaccine therapy) Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Given intranodally Other Names: CDX-1401 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies
Experimental: Cohort 1b (vaccine therapy and immunotherapy) Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Given intranodally Other Names: CDX-1401 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: Sirolimus Given PO or PEG Other Names: AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217
Experimental: Cohort 1c (vaccine therapy and immunotherapy) Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Given intranodally Other Names: CDX-1401 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: Sirolimus Given PO or PEG Other Names: AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217
Experimental: Cohort 1d (vaccine therapy and immunotherapy) Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Given intranodally Other Names: CDX-1401 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: Sirolimus Given PO or PEG Other Names: AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217
Experimental: Cohort 2 (vaccine therapy with or without immunotherapy) Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Given intranodally Other Names: CDX-1401 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: Sirolimus Given PO or PEG Other Names: AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217

Outcome Measures

Primary Outcome Measures

Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0 [Up to 12 months post-treatment]
The safe schedule of the combinatorial regimen is established at the dose before 2/6 patients experience dose-limiting toxicity. Estimated using a one-sided, 95%, exact binomial confidence interval (Clopper-Pearson).

Secondary Outcome Measures

NY-ESO-1 specific cellular immunity [Up to 12 months post-treatment]
Analyzed via an analysis-of-covariance (ANCOVA) model with post-treatment levels modeled as a function pretreatment levels and main effects corresponding to the 3 + 3 design.
NY-ESO-1 specific humoral immunity [Up to 12 months post-treatment]
ANCOVA model with post-treatment levels modeled as a function pretreatment levels and main effects corresponding to the 3 + 3 design.

Other Outcome Measures

Time to disease progression [Up to 12 months post treatment]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with any solid tumors at high risk of recurrence or with minimal residual disease; there may or may not be measurable or symptomatic disease (i.e., patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lungs, melanoma, ovarian, prostate, sarcomas, and uterine)
Cancer types:
Prostate cancer: patients with metastatic, castrate refractory prostate cancer; the use of luteinizing hormone-releasing hormone (LHRH) agonist is allowed
Kidney cancer: patients with metastatic kidney cancer; prior therapies with cytokines, vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (serine/threonine kinase) (mTOR) inhibitors are allowed
Bladder cancer: patients with metastatic urothelial carcinoma; prior cisplatin-based therapies are allowed
Ovarian cancer: eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen (CA)-125; or may be in complete clinical remission after treatment for primary or recurrent disease
Brain tumors: histologic proof of one of the following: glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic mixed glioma or anaplastic oligoastrocytoma; patients who have had recent cranial surgery are eligible for inclusion, but the vaccine may not be administered prior to postoperative day 14
Uterine cancer: patients with advanced (stages II-IV) or recurrent disease who have completed standard therapy, currently no evidence of disease (NED) or with minimal residual disease; patients with stage I uterine serous carcinomas or sarcomas are also eligible after completion of standard therapy
Breast cancer: patients can enter study after completion of all chemotherapy (including trastuzumab), radiation, and breast/axillary surgery; patients may participate while on endocrine therapy; stages I-III patients with the following characteristics:
Estrogen-receptor (ER) negative with positive lymph nodes; ER negative with negative nodes if tumor > 2 cm; ER positive with positive lymph nodes; and ER positive with negative lymph nodes and tumor > 5 cm
Sarcomas: patients with sarcomas of any site, who have completed standard therapy, and are in remission, or have minimal disease burden
Lungs: resected patients with hilar or ipsilateral mediastinal nodal disease (i.e., a subset of patients with stage II and IIIA disease); and patients with residual disease on imaging after definitive radiation or chemoradiation therapy
Esophageal: resected patients with any nodal (i.e., thoracic or abdominal) disease; and patients with residual disease on imaging after definitive chemoradiation therapy
Melanoma: stage IIB, stage IIC, and stage III who have completed planned definitive therapy for their disease including radiotherapy and/or interferon; patients declining interferon or with contra-indications to interferon will also be eligible provided they meet requisite criteria for this study (i.e., non-measurable disease); stage IV melanoma of M1a sub-type only, who are not candidates for additional therapy of curative potential (i.e., small volume disease; may be measurable or evaluable); and stage IV melanoma, NED, status post (s/p) complete resection of known sites of disease (i.e., non-measurable disease)
Hepatocellular carcinoma (HCC): patients who have been treated with surgical resection for HCC; and following chemoembolization as adjuvant therapy for HCC
Gastrointestinal: patients who have completed standard therapies for gastric and colorectal cancers, and deemed to be at high-risk of relapse
Any human leukocyte antigen (HLA) type; historic HLA typing is permitted
Tumor expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) and/or reverse transcription polymerase chain reaction (RTPCR)
Life expectancy > 6 months
Absolute neutrophil count (ANC) >= 1,000/uL
Platelets (PLT) >= 75,000/uL
Hemoglobin (Hgb) >= 8 g/dL
Total bilirubin =< 1.5 x upper limit of normal (ULN)
Serum aspartate aminotransferase (serum glutamic oxaloacetic transaminase [SGOT]/aspartate aminotransferase [AST]) or serum alanine aminotransferase (serum glutamate pyruvate transaminase [SGPT]/alanine aminotransferase [ALT]) =< 3 x ULN
Serum creatinine =< 2 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN; patients receiving anticoagulation therapy, PT/INR =< 3
Pulmonary function tests: forced expiratory volume in one second (FEV1) > 50% and diffusion capacity of the lungs for carbon monoxide (DLCO) > 50%
Pulse oximetry: oxygen (O2) saturation >= 90% on room air
Electrocardiogram, showing no clinical significant or acute abnormality
Have been informed of other treatment options
Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment

Exclusion Criteria:

Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)
History of severe autoimmune disorders requiring use of steroids or other immunosuppressives
Concomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, aspirin > 325 mg; specific cyclooxygenase (COX)-2 inhibitors are permitted
Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study agent (6 weeks for nitrosoureas); concomitant hormonal therapies for breast and prostate cancers are allowed
Clinically significant heart disease (New York Heart Association [NYHA] class III or

within 6 months

Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
Lack of availability of a patient for immunological and clinical follow-up assessment
Known pulmonary hypertension
Known hypersensitivity to sirolimus
Evidence of current drug or alcohol abuse or psychiatric impairment, which in the investigator's opinion will prevent completion of the protocol therapy or follow-up
Pregnant or nursing female patients
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study drug; (i.e., any significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the subject's risk by participating in this study)
Received an investigational agent within 30 days prior to enrollment
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)